Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 07 2021 - 4:05PM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage
biopharmaceutical company whose mission is to focus on unmet needs
and apply proven science and new technology to revolutionize
treatment for patients, starting with eye care, today announced
Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer
of Tarsus, will provide a brief corporate update at the Ladenburg
Thalmann 2021 Virtual Healthcare Conference.
Presentation DetailsDate: Wednesday, July
14Time: 1:30 PM ET/10:30 AM PTWebcast:
https://wsw.com/webcast/ladenburg7/tars/2438302
The live webcast will be hosted on ir.tarsusrx.com and available
for replay for a period of 90 days.
About Tarsus Pharmaceuticals,
Inc.Tarsus Pharmaceuticals, Inc. is a late clinical-stage
biopharmaceutical company that applies proven science and new
technology to revolutionize treatment for patients, starting with
eye care. It is advancing its pipeline to address several diseases
with high unmet need across a range of therapeutic categories,
including eye care, dermatology, and infectious disease prevention.
The company is studying two investigational medicines in clinical
trials. Its lead product candidate, TP-03, is a novel therapeutic
being studied in a second Phase 3 pivotal trial for the treatment
of Demodex blepharitis. TP-03 is also being developed for the
treatment of Meibomian Gland Disease. Tarsus is developing TP-05,
an oral, non-vaccine therapeutic for the prevention of Lyme
disease, which is currently being studied in a Phase 1 clinical
trial.
Media Contact: |
|
SuJin Oh |
|
Shop PR |
|
(917) 841-5213 |
|
sujin@shop-pr.com |
|
|
|
Investor Contact: |
|
Patti Bank |
|
Westwicke Partners, an ICR company |
|
(415) 513-1284 |
|
IR@tarsusrx.com |
|
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024